MPNs ☺️ Flashcards
Pathophysiology
Clonal proliferation of myeloid stem cells in BM
- RBC => polycythemia vera
- WBC => CML
- platelets => essential thrombocythemia
- fibroblasts => myelofibrosis
Polycythemia vera
- epidemiology and prognosis
- causes
- presentation
Often in older age, not usually inherited
Malignant proliferation of clone from pluripotent stem cell => excess proliferation of RBC, WBC, platelets
-JAK2 mutation common
Can be asymptomatic, incidental finding on FBC
Hyperviscosity symptoms
-fatigue, confusion
-headache
-visual changes
-itching after hot bath, burning in fingers and toes
Plethoric, splenomegaly, thrombosis
Can remain well
Risk of progressing to MF, AML
Polycythemia vera - investigations
FBC
- high RCC, Hb, haematocrit, PCV
- WCC, platelets can be high
Genetic testing - somatic mutation JAK2
US, kidneys, liver spleen - any organ enlargement
BMA - erythroid hyperplasia
Polycythemia vera
- management
- complications
Keep haematocrit low to keep thrombosis risk low
- venesection/hydroxycarbamide
- give aspirin
Monitor FBC 3monthly
-thrombosis, haemorrhage risk
Essential thrombocythemia
- epidemiology
- causes
- presentation
Often in older age, not usually inherited
Clonal proliferation of megakaryotes => high platelets with abnormal function
-JAK2 common
Clot formation, symptoms depend on location
- headache, dizzy, lightheaded
- chest pain
- visual changes
- numb hands and feet
- DVT, PE, thrombosis
Easy bleeding
-nosebleed, bruising, mouth/gums, bloody stools
Essential thrombocythemia - investigations
FBC - high platelets
Coagulation, platelet aggregation studies
Genetic testing - somatic mutation JAK2
US spleen
BMA - megakaryocytic proliferation
Essential thrombocythemia - management
Daily aspirin
-add hydroxycarbamide (chemo) if needed
Essential thrombocythemia -
- management
- prognosis
Daily aspirin
-add hydroxycarbamide (chemo) if needed
Does not reduce life expectancy
- chance of MF, AML progression
- risk of thrombosis, clots
Myelofibrosis
- epidemiology
- causes
- presentation
Middle, older adults
-JAK2 common
Often asymptomatic
B symptoms
Splenomegaly
BM failure - pancytopenia
Myelofibrosis
-investigations
FBC - anemia, WCC/platelets variable
Genetic testing - somatic mutation JAK2
US spleen
BMA - BM fibrosis
Myelofibrosis
- management
- prognosis
If symptomatic
BM support
-tranfusions
Splenomegaly
-chemo, radiation, targeted drugs
Allogenic BM stem cell transplants
Median survival - 4-5 years